Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

被引：4
|
作者：
Tombal, Bertrand
Borre, Michael
Rathenborg, Per
Werbrouck, Patrick
Heidenreich, Axel
Iversen, Peter
Baskin-Bey, Edwina S.
Perabo, Frank
Phung, De
Smith, Matthew Raymond
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Arhus Univ Hosp, Dept Urol, Skejby, Denmark
[3] Herlev Hosp, DK-2730 Herlev, Denmark
[4] AZ Groeninge Kortrijk, Kortrijk, Belgium
[5] Klin & Poliklin Urol, North Rhine Westphalia, Germany
[6] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark
[7] Astellas Pharma Europe Ltd, Staines, England
[8] Astellas Pharma Inc, Leiderdorp, Netherlands
[9] Astellas Pharma Europe BV, Leiderdorp, Netherlands
[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    Phung, De
    Smith, Matthew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC)
    Smith, Matthew Raymond
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Baskin-Bey, Edwina
    Perabo, Frank
    De Phung
    Tombal, Bertrand
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
    Tombal, Bertrand F.
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppet, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufi K.
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew R.
    LANCET ONCOLOGY, 2014, 15 (06): : 592 - 600
  • [5] A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer
    Corn, Paul G.
    Zhang, Miao
    Nogueras-Gonzalez, Graciela M.
    Xiao, Lianchun
    Zurita, Amado J.
    Subudhi, Sumit K.
    Tu, Shi-Ming
    Aparicio, Ana M.
    Coarfa, Cristian
    Rajapakshe, Kimal
    Huang, Shixia
    Navone, Nora M.
    Lin, Sue-Hwa
    Wang, Guocan
    Ramachandran, Sumankalai
    Titus, Mark A.
    Panaretakis, Theocharis
    Gallick, Gary E.
    Efstathiou, Eleni
    Troncoso, Patricia
    Logothetis, Christopher
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 990 - 999
  • [6] Enzalutamide (ENZA) monotherapy in hormone naive prostate cancer (HNPC): Complete analysis of a phase 2 study
    Smith, M.
    Borre, M.
    Rathenborg, P.
    Werbrouck, P.
    Van Poppel, H.
    Heidenreich, A.
    Iversen, P.
    Baskin-Bey, E.
    Perabo, F.
    Phung, D.
    Tombal, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S680
  • [7] A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Gao, Xin
    Smith, Matthew Raymond
    Scher, Howard I.
    Verholen, Frank
    Adorjan, Patrick
    Dissanayake, Manjari
    Laccetti, Andrew Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
    Kilari, Deepak
    Cuancial, Elizabeth A.
    Sahasrabudhe, Deepak M.
    Bylow, Kathryn A.
    Burfeind, John D.
    Musto, Kaylinn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)
    Kilari, D.
    Guancial, E.
    Sahasrabudhe, D.
    Bylow, K.
    Sievert, L.
    Schaffer, K.
    Riese, M.
    Burfeind, J.
    Musto, K.
    Feng, C.
    Messing, E.
    Mohile, S.
    Fung, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer
    Simons, JW
    Carducci, MA
    Mikhak, B
    Lim, M
    Biedrzycki, B
    Borellini, F
    Clift, SM
    Hege, KM
    Ando, DG
    Piantadosi, S
    Mulligan, R
    Nelson, WG
    CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3394 - 3401
12345